Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Anti-CD19 CAR T-cells for adults

David L. Porter • 9 Sep 2020
SOHO 2020
Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia General Leukemia Lymphoma Axicabtagene ciloleucel CAR-T Tisagenlecleucel

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, outlines the use of CD-19 CAR T-cells for adults with lymphoma and leukemia, specifically discussing the sustained remissions seen in patients treated with tisagenlecleucel and axicabtagene ciloleucel. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

More from David L. Porter

4:27
Impact of COVID-19 on CAR T-cell therapies
David L. Porter • 17 Sep 2020
5:25
Long-term outcomes of anti-CD19 CAR-T in R/R CLL
David L. Porter • 16 Sep 2020

Related Videos

5:15
CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
3:52
Outcomes of children and young adults with B-ALL following tisa-cel reinfusion
Kevin McNerney • 24 Feb 2023
3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter's transformation and R/R MCL
Nirav Shah • 15 Feb 2023
3:02
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Shah • 15 Feb 2023
The content of VJRegenMed is intended for healthcare professionals